Recent Updates
Recently added Catalysts
LNSR Positive Sentiment Score: 70/100

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Key Takeaway: LENSAR, Inc. has announced the release date for its third quarter 2024 financial results, which will be available before market opening on November 7, 2024. In conjunction with this release, the company will host a conference call and webcast to discuss its financial performance and recent company highlights. LENSAR is recognized for its advanced robotic laser solutions aimed at improving cataract treatment, underscoring its position in the medical technology field.

Market Sentiment Analysis

POSITIVE FACTORS

  • LENSAR is prepared to release its financial results, indicating ongoing business activity.
  • The upcoming conference call provides an opportunity for stakeholder engagement and insights.
  • The company's advanced robotic technologies may enhance surgical outcomes, appealing to investors.

Full Press Release Details

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
Contacts: Lee Roth / Cameron Radinovic
Thomas R. Staab, II, CFO Burns McClellan for LENSAR
ir.contact@lensar.com lroth@burnsmc.com / cradinovic@burnsmc.com

Frequently Asked Questions

When will LENSAR's Q3 2024 financial results be released?

LENSAR's Q3 2024 financial results will be released on November 7, 2024.

How can I participate in the LENSAR conference call?

Join the LENSAR conference call by dialing 800-715-9871 for domestic or 646-307-1963 for international calls.

What technology does the ALLY system use?

The ALLY system utilizes a dual-modality laser and integrates AI for advanced imaging and software.

Where can I watch the LENSAR webcast?

You can access the LENSAR webcast in the Investors section of their website.

What is LENSAR's focus in medical technology?

LENSAR focuses on developing advanced robotic laser solutions for cataract treatment.

Last updated: Oct 31, 2024